[3] [4] While taste disturbances have been reported by some patients taking GLP-1 receptor agonists, the documented frequency remains low compared to gastrointestinal effects
While this study was not a head-to-head clinical trial comparison, it may be relevant that at week 12 of a weekly dosing regimen, some studies suggest that participants treated with semaglutide (Wegovy, Novo Nordisk) had an approximately 6% decrease from baseline in body weight, whereas those treated with tirzepatide (Zepbound, Eli Lilly) had an approximately 8% decrease from baseline in body weight at the same time period, Bays said
10.1016/j.jnutbio.2014.03.007 38 DomicianoT
Conversely, women GLP-1 users experience higher rates of hospitalization for gallbladder surgery than men
Results may vary based on individual factors like dehydration levels and the severity of hangover symptoms
While using semaglutide you might consider asking your doctor for a CGM, a continuous glucose monitor
